CRISPR Therapeutics AG — Director's Dealing 2017

Dec 7, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CRISPR Therapeutics AG (CRSP)
CIK: 0001674416
Period of Report: 2017-11-03

Reporting Person: CELGENE CORP /DE/ (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-11-03	Common Stock	S	22759	$19.10	Disposed	4812221	Indirect
2017-11-06	Common Stock	S	79327	$18.89	Disposed	4732894	Indirect
2017-11-07	Common Stock	S	23000	$18.54	Disposed	4709894	Indirect
2017-11-08	Common Stock	S	16875	$18.06	Disposed	4693019	Indirect
2017-11-09	Common Stock	S	20000	$17.08	Disposed	4673019	Indirect
2017-11-10	Common Stock	S	10000	$17.28	Disposed	4663019	Indirect
2017-11-13	Common Stock	S	65093	$17.76	Disposed	4597926	Indirect
2017-11-14	Common Stock	S	14907	$17.19	Disposed	4583019	Indirect
2017-11-15	Common Stock	S	15000	$17.67	Disposed	4568019	Indirect
2017-11-16	Common Stock	S	105000	$18.39	Disposed	4463019	Indirect
2017-11-17	Common Stock	S	51282	$18.44	Disposed	4411737	Indirect
2017-11-20	Common Stock	S	158718	$19.02	Disposed	4253019	Indirect
2018-11-21	Common Stock	S	80000	$19.25	Disposed	4173019	Indirect
2017-11-22	Common Stock	S	256000	$19.76	Disposed	3917019	Indirect
2017-11-24	Common Stock	S	26010	$20.00	Disposed	3891009	Indirect
2017-11-27	Common Stock	S	27990	$19.75	Disposed	3863019	Indirect
2017-11-28	Common Stock	S	5080	$19.22	Disposed	3857939	Indirect
2017-11-29	Common Stock	S	4263	$19.25	Disposed	3853676	Indirect
2017-11-30	Common Stock	S	12666	$19.04	Disposed	3841010	Indirect
2017-12-01	Common Stock	S	87991	$19.10	Disposed	3753019	Indirect
2017-12-04	Common Stock	S	30485	$19.47	Disposed	3722534	Indirect

Footnotes

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from: $19.00 to $19.30 on 11/3/2017; $18.75 to $19.23 on 11/6/2017; $18.02 to $18.87 on 11/7/2017; $17.93 to $18.35 on 11/8/2017; $17.00 to $17.50 on 11/9/2017; $17.10 to $17.46 on 11/10/2017; $17.50 to $17.99 on 11/13/2017; $17.03 to $17.45 on 11/14/2017; $17.55 to $17.75 on 11/15/2017, inclusive. The reporting person undertakes to provide any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4

F2: These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation ("Celgene"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities.

F3: Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from: $17.86 to $18.57 on 11/16/2017; $18.30 to $18.65 on 11/17/2017; $18.60 to $19.26 on 11/20/2017; $19.02 to $19.46 on 11/21/2017; $19.20 to $20.01 on 11/22/2017; $19.84 to $20.27 on 11/24/2017; $19.41 to $20.20 on 11/27/2017; $19.00 to $19.76 on 11/28/2017; $19.20 to $19.39 on 11/29/2017; $19.00 to $19.20 on 11/30/2017; $19.02 to $19.22 on 12/1/2017; and $19.20 to 19.64 on 12/4/2017, inclusive. The reporting person undertakes to provide any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.